Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412
Download
Date
2020-06-03Source Title
Future OncologyPublisher
FUTURE MEDICINE LTDAffiliation
Medicine (St Vincent's)Metadata
Show full item recordDocument Type
Journal ArticleCitations
Machiels, J. -P., Tao, Y., Burtness, B., Tahara, M., Licitra, L., Rischin, D., Waldron, J., Simon, C., Gregoire, V., Harrington, K., Alves, G. V., Lima, I. P. F., Pointreau, Y., Hughes, B. G. M., Aksoy, S., Hetnal, M., Ge, J. Y., Brown, H., Cheng, J. ,... Siu, L. L. (2020). Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. FUTURE ONCOLOGY, 16 (18), pp.1235-1243. https://doi.org/10.2217/fon-2020-0184.Access Status
Open AccessAbstract
Current treatment guidelines for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) recommend multimodal treatment, including chemoradiation therapy (CRT) or surgery followed by radiation, with or without chemotherapy. The immune checkpoint inhibitor pembrolizumab has previously demonstrated antitumor activity in recurrent and/or metastatic HNSCC in large Phase III trials. For patients with locally advanced disease, Phase Ib data on the use of pembrolizumab in combination with chemoradiation have shown the approach to be safe and feasible. We describe here the design and rationale for KEYNOTE-412, a randomized, double-blind, Phase III trial investigating pembrolizumab or placebo administered concurrently with CRT and as maintenance treatment in patients with locally advanced HNSCC.
Export Reference in RIS Format